- October 1, 2012 | BY
Each year in the US, approximately 3,000 children are diagnosed with leukemia, the most common childhood cancer. This cancer of the blood makes up one-third of cancer cases in children and is the leading cause of death in children up to age 14. Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in ...
- September 24, 2012 | BY
Two broad types of cancer vaccines exist: preventive cancer vaccines, which target infectious agents causing cancer development, and therapeutic vaccines, which treat an existing cancer by strengthening the body’s natural defense.
- September 21, 2012 | BY
A highly publicized event perpetuated myths of harm from the MMR vaccine.
- September 20, 2012 | BY
I’m part of the generation who vividly remembers mumps’ high fever and the itching from chicken pox.
- September 18, 2012 | BY
Most of our communities have access to effective and safe medicines as well as preventative vaccines, a far cry from seven decades ago when polio filled famlies with dread.
- September 10, 2012 | BY
We’re all familiar with the common symptoms of the flu, but what we may not know is that there are a number of complications that can result from it, particularly in young children and the elderly.
- September 7, 2012 | BY
Seth Berkley, an expert on vaccine design, discusses how vaccines of the future might put an end to global threats such as the flu and malaria.
- August 27, 2012 | BY
With its many anatomical, physiological and functional similarities to humans, the miniature pig (minipig, Sus scrofa) has become a viable alternative to non-rodent animal models in nonclinical safety testing.
- August 14, 2012 | BY
Ipilimumab and other cancer biologics like it are based on natural antibodies, slightly changed to give them the long-acting characteristics of the natural form as well as the ability to target proteins on specific cells.
- August 8, 2012 | BY
While photosafety testing has been an important part of preclinical drug development for over 30 years, it’s poorly understood as to the accepted methodologies, when to initiate evaluation, the expectations of the regulatory agencies, and how to interpret results. The lack of clarity in current regulatory guidances, controversy over the interpretation of in vitro assays ...